We’ve been creating innovative medicine with our partners for over 40 years. Lead by Dr. Fred D. Sancilio, SCI’s heritage began at Applied Analytical Industries (AAI), probably the first contract research organization in the United States. There Sancilio led development programs supporting such brands as Prilosec, Nexium, Stridex, Benadryl and over 1,000 drug product approvals. Sancilio continued to grow his skills and built several innovative biotech companies including Aesgen, a partnership with the Mayo Clinic and Endeavor, a partnership with Schering, Ag.
Years later, Sancilio and Company evolved into a premier resource for growing young companies seeking to avoid pitfalls that can derail even the best programs. Today, Sancilio and Company is leading efforts to treat diseases that were once thought of as untreatable. Ongoing development work with partners focus on Sickle Cell Disease, Alzeheimer’s, ALS and Covid-19.
We aim to build value-creating partnerships with our global network of entrepreneurs, academicians and scientists allowing products to reach market expeditiously and cost effectively.
Through our global network, we identify product opportunities and work with our partners to advance them from concept to market.
We provide our four decades of experience to shape programs uniquely for each opportunity. We may enter into development agreements where we manage the entire process from discovery to marketing and distribution, or we may help find investors to support selected programs.
Need a contract manufacturer, ingredient supplier or specialty analysis; you can benefit from our 40 years of experience and avoid mistakes made by many who try to go it alone.